In fact, it seems clear that only some specific subgroups of prostate cancer patients—including those with PD-L1 positive and TMB high tumors—could really benefit from PD-(L)1 blockade, even if response to immunotherapy seems to be independent from PD-L1 expression [92]. The gene discussed is CD274; the disease is prostate cancer.